STAAR Surgical

STAAR Surgical reported Q2 2026 revenue of $93.5 million (+111% YoY), beating analyst estimates, while adjusted EPS of $0.16 missed the consensus of $0.22. China was the main growth driver with $52.3 million; excluding China, revenue rose just 6% to $41.2 million. The company returned to profit, improved gross margin and EBITDA, and holds $181.5 million in cash with zero debt. Management expects seasonally lower China revenue in Q3, but still sees growth for 2026 and plans production relocations to Switzerland as well as easing of EVO+ supply constraints by the end of Q3. » Más en de.investing.com

STAAR Surgical’s board of directors has appointed Warren Foust, effective immediately, as president and chief executive officer and as a member of the board. Foust had been with STAAR since April 2023 and most recently served as interim co‑CEO, president and COO; previously he held leadership roles at Johnson & Johnson, DePuy Synthes, Aventis and Roche. Deborah Andrews will become executive vice president and will remain chief financial officer. The appointments follow a global search; the company makes phakic intraocular lenses and has sold more than 4 million lenses in over 85 countries. » Más en de.investing.com

STAAR Surgical reported preliminary net sales for Q2 2026 of over $90 million, more than double year‑on‑year but in line with the consensus estimate of about $90.2 million. The result triggered a sell‑the‑news reaction; the stock fell as much as 8.4% in premarket trading and later partially recovered. Canaccord Genuity reaffirmed its buy rating and $32 price target but said it will adjust estimates only after the full Q2 figures on August 12. Weighing on the stock were the lack of an official forecast, the interim dual leadership, a slight revenue decline in EMEA due to unrest in the Middle East, and a weak overall market environment. » Más en de.investing.com

STAAR Surgical reported record Q1 2026 results: revenue $93.5m (+119.6% y/y) and EPS of $0.10 after a loss in the prior year. Growth was driven by the launch of the EVO+ ICL in China and an improved gross margin from 65.8% to 73.6%. Analyst responses (including Wedbush target $40, Piper Sandler target $33) and short-covering amplified the rally; the stock climbed about 14.5% intraday to a 52-week high of $35.87. Additional catalysts include a potential FDA age-label expansion in the US and Swiss production to avoid import tariffs into China. » Más en de.investing.com

STAAR Surgical reported Q1 2026 EPS of $0.10 (forecast $0.05) and revenue of $93.5 million, up 119.6% year‑over‑year. Adjusted EBITDA was $24.4 million and operating income $8.0 million. The strong growth was driven mainly by China ($47.4 million); the stock rose 4.33% in after‑hours trading. Management issued optimistic guidance with EPS forecasts of $0.17 for Q2 and $0.19 for Q3 and a Q2 revenue expectation of $84 million. » Más en de.investing.com